Table 3 Maspin expression in bladder cancer
From: Role of maspin in cancer
| Authors | Years | N. patients | Maspin expression | Clinical features/prognosis |
|---|---|---|---|---|
| Acikalin et al. | 2012 | 68 (T1 bladder cancer) | Not specified | Positive maspin = longer PFS and less recurrence |
| Negative maspin = shorter PFS and more recurrence | ||||
| Kramer at al. | 2010 | 162 (pTa-pT1 bladder cancer) | 75.9% positive maspin | Positive maspin = PFS: 46 months |
| 24.1% negative maspin | Negative maspin = PFS: 18 months | |||
| Friedrich et al. | 2004 | 110 (pTa-pT1 bladder cancer) | 33.6% positive maspin | Positive maspin = PFS: 29 months, MVD: 17.7(CD34) and 6.0 (CD105)per field |
| 66.4%negative maspin | Negative maspin = PFS: 23 months, MVD = 21.7 (CD34) and 4.2 (CD105)per field | |||
| Sugimoto et al. | 2004 | 65 (22 transurethral resection and 43 radical resection specimens) | 18.2%positive maspin in transurethral resection specimens | Positive maspin = progression from invasive bladder cancer |
| 51.2% positive maspin in radical resection specimens | ||||
| Nehad et al. | 2010 | 134 (56 squamous cell carcinoma (scc)and 78 transitional urinary bladder(tcc)) | 53.7% positive maspin (42.8% scc and 61.5% tcc) | Positive maspin = 91.7% low grade |
| 46.3% negative maspin | Negative maspin = 54.8% high grade | |||
| Blandamura et al. | 2008 | 66 (48 pTa e 18 pT1) | 38% positive maspin | 60.5% positive maspin have high grade |
| 62% negative maspin | 22.44% positive maspin have low grade |